These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 24919969)

  • 1. Visual short-term memory deficits associated with GBA mutation and Parkinson's disease.
    Zokaei N; McNeill A; Proukakis C; Beavan M; Jarman P; Korlipara P; Hughes D; Mehta A; Hu MT; Schapira AH; Husain M
    Brain; 2014 Aug; 137(Pt 8):2303-11. PubMed ID: 24919969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visual short-term memory deficits in REM sleep behaviour disorder mirror those in Parkinson's disease.
    Rolinski M; Zokaei N; Baig F; Giehl K; Quinnell T; Zaiwalla Z; Mackay CE; Husain M; Hu MT
    Brain; 2016 Jan; 139(Pt 1):47-53. PubMed ID: 26582557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.
    Neumann J; Bras J; Deas E; O'Sullivan SS; Parkkinen L; Lachmann RH; Li A; Holton J; Guerreiro R; Paudel R; Segarane B; Singleton A; Lees A; Hardy J; Houlden H; Revesz T; Wood NW
    Brain; 2009 Jul; 132(Pt 7):1783-94. PubMed ID: 19286695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel Parkinson's disease risk variant, p. W378R, in the Gaucher's disease GBA gene.
    Lubomski M; Hayes M; Kennerson M; Ellis M; Chu S; Blackie J; O'Sullivan JD; Nicholson G
    Mov Disord; 2018 Oct; 33(10):1662-1664. PubMed ID: 30216542
    [No Abstract]   [Full Text] [Related]  

  • 5. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.
    Fishbein I; Kuo YM; Giasson BI; Nussbaum RL
    Brain; 2014 Dec; 137(Pt 12):3235-47. PubMed ID: 25351739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.
    Beavan M; McNeill A; Proukakis C; Hughes DA; Mehta A; Schapira AH
    JAMA Neurol; 2015 Feb; 72(2):201-8. PubMed ID: 25506732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Features of
    Malek N; Weil RS; Bresner C; Lawton MA; Grosset KA; Tan M; Bajaj N; Barker RA; Burn DJ; Foltynie T; Hardy J; Wood NW; Ben-Shlomo Y; Williams NW; Grosset DG; Morris HR;
    J Neurol Neurosurg Psychiatry; 2018 Jul; 89(7):702-709. PubMed ID: 29378790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of prodromal parkinsonian features in a cohort of
    Avenali M; Toffoli M; Mullin S; McNeil A; Hughes DA; Mehta A; Blandini F; Schapira AHV
    J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1091-1097. PubMed ID: 31221723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
    McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
    Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes.
    Alcalay RN; Dinur T; Quinn T; Sakanaka K; Levy O; Waters C; Fahn S; Dorovski T; Chung WK; Pauciulo M; Nichols W; Rana HQ; Balwani M; Bier L; Elstein D; Zimran A
    JAMA Neurol; 2014 Jun; 71(6):752-7. PubMed ID: 24756352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.
    Liu G; Boot B; Locascio JJ; Jansen IE; Winder-Rhodes S; Eberly S; Elbaz A; Brice A; Ravina B; van Hilten JJ; Cormier-Dequaire F; Corvol JC; Barker RA; Heutink P; Marinus J; Williams-Gray CH; Scherzer CR;
    Ann Neurol; 2016 Nov; 80(5):674-685. PubMed ID: 27717005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.
    Alcalay RN; Caccappolo E; Mejia-Santana H; Tang M-; Rosado L; Orbe Reilly M; Ruiz D; Ross B; Verbitsky M; Kisselev S; Louis E; Comella C; Colcher A; Jennings D; Nance M; Bressman S; Scott WK; Tanner C; Mickel S; Andrews H; Waters C; Fahn S; Cote L; Frucht S; Ford B; Rezak M; Novak K; Friedman JH; Pfeiffer R; Marsh L; Hiner B; Siderowf A; Payami H; Molho E; Factor S; Ottman R; Clark LN; Marder K
    Neurology; 2012 May; 78(18):1434-40. PubMed ID: 22442429
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Riboldi GM; Di Fonzo AB
    Cells; 2019 Apr; 8(4):. PubMed ID: 31010158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.
    Aharon-Peretz J; Rosenbaum H; Gershoni-Baruch R
    N Engl J Med; 2004 Nov; 351(19):1972-7. PubMed ID: 15525722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.
    Barkhuizen M; Anderson DG; Grobler AF
    Neurochem Int; 2016 Feb; 93():6-25. PubMed ID: 26743617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of GBA for Parkinson's disease.
    Brockmann K; Berg D
    J Inherit Metab Dis; 2014 Jul; 37(4):643-8. PubMed ID: 24894157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort.
    Winder-Rhodes SE; Evans JR; Ban M; Mason SL; Williams-Gray CH; Foltynie T; Duran R; Mencacci NE; Sawcer SJ; Barker RA
    Brain; 2013 Feb; 136(Pt 2):392-9. PubMed ID: 23413260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.
    Behl T; Kaur G; Fratila O; Buhas C; Judea-Pusta CT; Negrut N; Bustea C; Bungau S
    Transl Neurodegener; 2021 Jan; 10(1):4. PubMed ID: 33446243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.